Moragrega Adame J L, Peña Vincent H
Servicio de Cardiología, Hospital Central, Petróleos Mexicanos, D. F.
Arch Inst Cardiol Mex. 1976 May-Jun;46(3):317-24.
In order to evaluate the clinical efficacy on penbutolol (Hoe 893 d), a new adrenergic blocking agent, two groups of 10 patients (A & B) with ischemic heart disease were chosen. These were submitted to exercise testing for 3 minutes, and placebos, nitroglycerin, and propranolol were used as reference preparations. As an index of indirect consumption of oxygen we determined the maximum cardiac frequency (MCF), maximum systolic arterial pressure (MAP) and the maximum double product (MDP). An electrocardiographic control of the patients was also included to observe ST segment changes. The patients from group A received 0.8 mg. of nitroglycerin sublingual as the first treatment and 40 mg. of propranolol as the second. The patients from group B received initially a placebo P.O. and then 25 mg. of penbutolol P.O. In both groups the exercise testing was repeated 10 minutes after the administration of the first substance and 10 minutes after the second. The results showed that 25 mg. of penbutolol and 40 mg. of propranolol have similar therapeutic effects over the degree, intensity, and duration of the differences in elevation of the ST segment, MCF, MAP, and MDP when you compare the results of their own controls with those obtained with the active principle. There is no significant difference observed in the results obtained in each parameter studied between penbutolol and propranolol. During the period of this clinical study there were no undesirable collateral effects caused by the oral administration of the investigated drugs.
为评估新型肾上腺素能阻滞剂喷布洛尔(Hoe 893 d)的临床疗效,选取两组各10例缺血性心脏病患者(A组和B组)。让这些患者进行3分钟运动试验,并使用安慰剂、硝酸甘油和普萘洛尔作为对照制剂。作为间接耗氧量指标,我们测定了最大心率(MCF)、最大收缩动脉压(MAP)和最大双乘积(MDP)。还对患者进行心电图监测以观察ST段变化。A组患者首先舌下含服0.8 mg硝酸甘油作为首次治疗,然后口服40 mg普萘洛尔作为第二次治疗。B组患者首先口服安慰剂,然后口服25 mg喷布洛尔。两组患者在给予第一种药物后10分钟以及给予第二种药物后10分钟重复进行运动试验。结果显示,当将喷布洛尔和普萘洛尔自身对照结果与活性成分所得结果相比较时,25 mg喷布洛尔和40 mg普萘洛尔在ST段抬高、MCF、MAP和MDP差异的程度、强度和持续时间方面具有相似的治疗效果。在喷布洛尔和普萘洛尔之间,在所研究的每个参数结果中均未观察到显著差异。在该临床研究期间,口服所研究药物未引起不良副作用。